In China, apart from osimertinib, furmonertinib, a pan-EGFR TKI with CNS antitumor activity, and aumolertinib, formerly almonertinib, an oral EGFR-TKI that is selective for mutant EGFR over wild-type EGFR, have demonstrated efficacy for EGFR mutated NSCLC and were approved in China for the treatment of locally advanced, metastatic NSCLC with confirmed EGFR T790M mutation whose disease has progressed during or after EGFR TKI therapy (Shi et al., 2022; Bao et al., 2016; Lu et al., 2022; Yang et al., 2020). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.